Atrium Medical Corporation Announces Formation of Biosurgery Division

HUDSON, NH--(Marketwire - January 12, 2009) -

Highlighted Links

www.atriummed.com

Atrium Medical Corporation® is pleased to announce the formation of its newest med-tech specialty healthcare division, Atrium Biosurgery™. Atrium Biosurgery is dedicated to the development of pioneering advancements in biological, mechanical and therapeutic solutions for soft tissue healing following trauma, surgery and or other interventional procedures that require improved patient recovery and prospects for improved healing outcomes. This newest global expansion will complement Atrium's other professional Healthcare Divisions -- Cardiovascular Interventions (CVI) and Cardiothoracic Surgery (CTS) -- by continuing the company's tradition of providing state-of-the-art medical device technology for patients around the globe.

Atrium Biosurgery products include Atrium's first-to-market Omega 3 Bioabsorbable Oil Fatty Acid (O3FA) coated medical devices. This novel technology combines Atrium's ProLite™ and ProLite Ultra™ brand polypropylene surgical mesh products commonly used in soft tissue and hernia repair with a proprietary, pharmaceutical grade Omega 3 bio-absorbable coating. Atrium's innovative discovery of combining an inert thin wall polypropylene mesh with an all natural Omega 3 biological coating in clinical use, and in numerous pre-clinical studies, has demonstrated minimization of visceral tissue attachment as well as reductions in both foreign body reaction and inflammation following surgical intervention. Such technology can result in a preferred, well healed, reinforced surgical repair. These soft tissue reinforcement devices include Atrium C-QUR™ Mesh, C-QUR Edge™ Mesh, and the recently launched C-QUR Lite™ Surgical Mesh which combine a proven inert polymer material with an advanced Omega 3 coating technology -- indicated for use in the surgical repair and reinforcement of soft tissue, including abdominal and inguinal hernia surgery, common surgical procedures performed more than 700,000 times annually in the US.

With the introduction of the new Atrium Biosurgery Division, the company is undergoing a substantial expansion program and is anticipating exceptional growth as several pending new O3FA technology based products become commercially available in the months and years ahead.

About Atrium®

Atrium's vast expertise in medical device technologies for the treatment of coronary and vascular disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, women's health and general surgery. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcome. For more information please call Atrium's Marketing Communications Dept. at 1-800-370-7899 or Google® Atrium Medical, and visit us on the web at www.atriummed.com.